Phibro Animal Health (NASDAQ:PAHC) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Phibro Animal Health (NASDAQ:PAHC) issued its quarterly earnings data on Wednesday. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14, FiscalAI reports. The company had revenue of $396.75 million during the quarter, compared to the consensus estimate of $381.18 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health updated its FY 2027 guidance to 3.410-3.590 EPS.

Phibro Animal Health Stock Performance

PAHC opened at $36.09 on Thursday. The company has a market cap of $1.46 billion, a P/E ratio of 15.49, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm’s 50-day moving average price is $33.95 and its 200-day moving average price is $42.44. Phibro Animal Health has a 52-week low of $28.25 and a 52-week high of $60.08.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio is 20.60%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health during the third quarter worth $61,000. EverSource Wealth Advisors LLC lifted its position in Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after acquiring an additional 2,685 shares during the period. C M Bidwell & Associates Ltd. grew its stake in Phibro Animal Health by 1,756.5% during the 4th quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock valued at $80,000 after purchasing an additional 2,020 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after purchasing an additional 4,079 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Finally, Citigroup decreased their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $42.50.

Key Stories Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Quarterly results beat forecasts: Fourth-quarter revenue rose approximately 5% year over year to $396.7 million, topping the $381.2 million analyst estimate. Reported EPS was $0.85 versus the $0.71 consensus estimate. Phibro fourth-quarter results and guidance
• Positive Sentiment: Profitability improved: Net income attributable to common shareholders increased more than 26% year over year to $21.7 million, while diluted EPS was reported at $0.53 in one financial-data summary. Gross profit increased to $134.4 million and operating profit reached $48.2 million, indicating stronger margins and operating execution. Phibro stock rises on fiscal 2026 earnings
• Positive Sentiment: Above-consensus outlook: Phibro forecast fiscal 2027 EPS of $3.41 to $3.59, ahead of the $3.34 analyst consensus, and revenue of approximately $1.6 billion versus a $1.5 billion consensus. The guidance suggests management expects continued growth. Phibro earnings and guidance details
• Neutral Sentiment: Operating cash flow remained positive at $24.1 million, although capital expenditures totaled $18.9 million. Cash stood at $61.4 million against total liabilities of $1.2 billion.
• Negative Sentiment: Insider trading data showed 48 sales and only one purchase over the past six months, including substantial selling by CEO Jack Bendheim. This may temper investor enthusiasm despite the strong earnings report. Phibro insider trading activity

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.